EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries

European Journal of Preventive Cardiology

Volumn 23, Issue 6, 2016, Pages 636-648

  Kotseva, Kornelia ^a,b   Wood, David ^a,b   De Bacquer, Dirk ^a,c   De Backer, Guy ^a,c   Rydén, Lars ^a,d   Jennings, Catriona ^a,b   Gyberg, Viveca ^d   Amouyel, Philippe ^e   Bruthans, Jan ^a,f   Castro Conde, Almudena ^g   Cífková, Renata ^a,f   Deckers, Jaap W ^a,h   De Sutter, Johan ^a,c   Dilic, Mirza ^a,i   Dolzhenko, Maryna ^j   Erglis, Andrejs ^a,k   Fras, Zlatko ^a,l   Gaita, Dan ^a,m   Gotcheva, Nina ⁿ   Goudevenos, John ^a,o   Heuschmann, Peter ^p   Laucevicius, Aleksandras ^a,q   Lehto, Seppo ^r   Lovic, Dragan ^a,s   Mili, Davor ^a,t   Moore, David ^u   Nicolaides, Evagoras ^a,v   Oganov, Raphael ^w   Pajak, Andrzej ^x   Pogosova, Nana ^a,w   Reiner, Zeljko ^a,y   Stagmo, Martin ^z   Störk, Stefan ^aa   Tokgözolu, Lale ^a,ab   Vulic, Dusko ^a,ac   more..

^a European Society of Cardiology   (France)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c GHENT UNIVERSITY   (Belgium)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIV LILLE   (France)

^f CHARLES UNIVERSITY   (Czech Republic)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h Department of Cardiology H538   (Netherlands)

ⁱ UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^j SHUPYK NATIONAL MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Ukraine)

^k PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^l UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^m VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

ⁿ National Heart Hospital   (Bulgaria)

^o UNIVERSITY OF IOANNINA   (Greece)

^p UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^q VILNIUS UNIVERSITY   (Lithuania)

^r KUOPIO UNIVERSITY HOSPITAL   (Finland)

^s Clinic for Internal Medicine Intermedica   (Serbia)

^t UNIVERSITY OF ZAGREB   (Croatia)

^u ADELAIDE AND MEATH HOSPITAL   (Ireland)

^v UNIVERSITY OF NICOSIA   (Cyprus)

^w NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

^x JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^y KBC Zagreb   (Croatia)

^z LUND UNIVERSITY HOSPITAL   (Sweden)

^aa UNIVERSITY OF WÜRZBURG   (Germany)

^ab HACETTEPE UNIVERSITY   (Turkey)

^ac UNIVERSITY OF BANJA LUKA   (Bosnia and Herzegovina)

more..

Author keywords

cardiovascular prevention; EUROASPIRE; guidelines; rehabilitation

Indexed keywords

AMFEBUTAMONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VARENICLINE; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BELGIUM; BLOOD PRESSURE MEASUREMENT; BODY MASS; BOSNIA AND HERZEGOVINA; BULGARIA; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RISK; CROATIA; CROSS-SECTIONAL STUDY; CYPRUS; CZECH REPUBLIC; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ELEVATED BLOOD PRESSURE; FEMALE; FINLAND; FRANCE; GERMANY; GREECE; HEART REHABILITATION; HUMAN; IRELAND; LATVIA; LIFESTYLE; LITHUANIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; NETHERLANDS; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL ACTIVITY; POLAND; PRACTICE GUIDELINE; PRIORITY JOURNAL; ROMANIA; RUSSIAN FEDERATION; SECONDARY PREVENTION; SERBIA; SLOVENIA; SMOKING; SMOKING CESSATION; SPAIN; SWEDEN; SYSTOLIC BLOOD PRESSURE; TURKEY (REPUBLIC); UKRAINE; UNITED KINGDOM; VERY ELDERLY; WAIST CIRCUMFERENCE; ADOLESCENT; ADULT; ADVERSE EFFECTS; CARDIOLOGY; CLINICAL TRIAL; COMORBIDITY; CORONARY DISEASE; DIET; EUROPE; EXERCISE; HEALTH CARE SURVEY; MEDICAL SOCIETY; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDY; PROTOCOL COMPLIANCE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEDENTARY LIFESTYLE; TIME FACTOR; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARDIOLOGY; CARDIOVASCULAR AGENTS; COMORBIDITY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIET; EUROPE; EXERCISE; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; SEDENTARY LIFESTYLE; SMOKING; SMOKING CESSATION; SOCIETIES, MEDICAL; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959880392     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315569401     Document Type: Article

References (45)

1. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerotic Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-1331.
2. Wood D, De Backer G, Faergeman D, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998; 19: 1434-1503.
3. De Backer G, Ambrosioni E, Borch-johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10 (Suppl. 1): S1-S78.
4. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl. 2): S1-S113.
5. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33: 1635-1701.
6. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18: 1569-1582.
7. EUROASPIRE Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-572.
8. EUROASPIRE Study Group. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
9. Kotseva K, Wood D, De Backer G, et al. on behalf of EUROASPIRE III Study Group. EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121-137.
10. Kotseva K, Wood D, De Backer G, et al. on behalf of EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-940.
11. Bartnik M, Rydén L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 1880-1890.
12. Lenzen M, Rydén L, Ohrvik J, et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: A report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2006; 27: 2969-2974.
13. Anselmino M, Bartni M, Öhrvik J, et al. The Euro Heart Survey on diabetes and the heart. Int Diabetes Monitor 2010; 22: 1-9.
14. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
15. Lean MEJ, Han TS, Morrison CE,. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158-161.
16. Middleton ET, Morice AH,. Breath carbon monoxide as an indication of smoking habit. Chest 2000; 117: 758-763.
17. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
18. Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mortality after myocardial infarction: Meta-analysis of cohort studies. Arch Intern Med 2000; 160: 939-944.
19. Chritchley J, Capewell S,. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. JAMA 2003; 290: 86-97.
20. Jennings C, Kotseva K, DeBacquer D, et al. on behalf of EUROACTION PLUS Study Group. Effectiveness of a preventive cardiology programme for high CVDrisk persistent smokers: The EUROACTION PLUS Varenicline trial. Eur Heart J 2014; 35: 1411-1420.
21. Rigotti NA, Munafo MR, Stead LF,. Smoking cessation interventions for hospitalized smokers: A systematic review. Arch Intern Med 2008; 168: 1950-1960.
22. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219.
23. Law MR, Morris JK, Wald NJ,. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
24. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
25. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
26. Rydén L, Grant P, Anker S, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in colaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-3087.
27. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
28. Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 394-403.
29. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008; 155: 772-779.
30. Rasmussen JN, Chong A, Alter DA,. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 177.
31. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15.
32. Heran BS, Chen JM, Ebrahim S, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev (Online) 2011 7. CD001800.
33. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: Systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116: 682-692.
34. Clark AM, Hartling L, Vandermeer B, et al. Meta-analysis: Secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005; 143: 659-672.
35. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121: 750-758.
36. Kotseva K, Wood D, De Backer G, et al. Use and effects of cardiac rehabilitation in patients with coronary heart disease: Results from the EUROASPIRE III survey. Eur J Prev Cardiol 2013; 20: 817-826.
37. Wood DA, Kotseva K, Connolly S, et al. on behalf of EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008; 371: 1999-2012.
38. Giannuzzi P, Temporelli PL, Marchioli R, et al. for the GOSPEL Investigators. Global secondary prevention strategies to limit event recurrence after myocardial infarction: Results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med 2008; 168: 2194-2204.
39. De Smedt D, Kotseva K, De Bacquer D, et al. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: The EUROASPIRE III health economics project. Eur Heart J 2012; 33: 2865-2872.
40. Mehta RH, Bhatt DL, Steg PG, et al. on behalf of the REACH Registry Investigators. Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: Insights from the REACH registry. Eur Heart J 2008; 29: 3052-3060.
41. Mendis S, Abegunde D, Yusuf S, et al. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 2005; 83: 820-828.
42. Vedin O, Hagstrom E, Stewart R, et al. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: Baseline results from the STABILITY study. Eur J Prev Cardiology 2013; 20: 678-685.
43. Teo K, Lear S, Islam S, et al. PURE Investigators. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. JAMA 2013; 309: 1613-1621.
44. Yusuf S, Islam S, Chow CK, et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet 2011; 378: 1231-1243.
45. Galea S, Tracy M,. Participation rates in epidemiologic studies. Ann Epidemiol 2007; 17: 643-653.